优时比贸易（上海）有限公司

Headquartered in Brussels (Belgium), UCB (ww***com[点击查看]) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. The company combines passion for innovation with a mission to provide therapeutic solutions for patients with severe diseases treated by specialists. Employing more than 8,400 people in over 40 countries, UCB achieved revenues of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange.



UCB China’s business started in 1995. Zyrtec is widely prescribed in China to treat allergy patients. Keppra, recently launched in China in 2007, is one of the top products for UCB and is a new treatment for epilepsy that has already been successfully commercialized in several countries. The revenue for Keppra in 2006 was 761 million euro (growth of 36% as compared to 2005). Today, Keppra is the most successful new treatment for epilepsy in the USA. As UCB is to expand quickly in China and with the launch of new products in the fields of Allergy and Central Nervous System (CNS), we are inviting high-caliber individuals to join UCB China.

作为全球领先的生物制药公司，总部设在比利时布鲁塞的优时比（UCB）公司，秉承造福人类的使命，在近八十年的发展中，为全球重症疾病患者提供了若干独具特色的药物。优时比（UCB）公司通过采用创新的方式进行化学药品与生物药品的研究与开发，主要致力于中枢神经系统疾病，过敏/呼吸系统疾病、自身免疫疾病及肿瘤疾病的治疗领域的研究。在重症疾病治疗领域中，优时比（UCB）公司始终处于先行者的地位。在全球40多个国家拥有8,400多名员工，2006年，优时比（UCB）公司实现收入25亿欧元，优时比（UCB）公司在欧洲布鲁塞尔证券交易市场上市。



优时比（UCB）公司在中国的业务始于1995年，总部设在上海。其专利产品仙特明和优泽被广泛用于治疗过敏疾病患者。其专利产品“开浦兰”作为新一代抗癫痫药，用于癫痫病的治疗并成为美国最成功的治疗癫痫的产品之一。作为优时比（UCB）公司顶级产品之一，开浦兰2006年在全球的销售已达到7.6亿欧元（与2005年相比增长了36%）， 日前，“开浦兰”已经在中国上市。由于优时比（UCB）公司在中国业务高速发展的需要，我们诚邀各路人才加入优时比（UCB）公司，与优时比（UCB）在中国一同成长。